에 대한 최신 뉴스 OPKO Health (NASDAQ:OPK) 주식

OPKO Health

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.

News

Health Care

After-Hours Center

Movers

옵코 헬스(NASDAQ:OPK)의 주가는 수요일 시장 마감 후 시간외 거래에서 상승했다. 이 회사는 헬스케어 로열티(HCRx)와 2억 5천만 달러 규모의 희석되지 않은 채권 구매 계약을 체결했다고 발표했다.

옵코 헬스의 주식이 수요일 애프터마켓에서 상승한 이유는?

OPKO Health Inc

Digital Holdings Inc

HC Wainwright &amp; Co. analyst Yi Chen maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Buy and maintains $3 price target.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on OPKO Health, Maintains $3 Price Target

WIIM

Merck & Compnay and OPKO Health shares are trading higher after the companies announced a license and collaboration agreement to develop an Epstein-Barr virus vaccine.

OPKO Health's ModeX Therapeutics Begins Phase I Trial For Epstein-Barr Virus Vaccine In Collaboration With Merck; First Participant Dosed, Milestone Payment Triggered By Merck

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and maintains $2.25 price target.

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. The company reported quarterly sales of $173.600 million which missed the analyst consensus estimate of $181.525 million by 4.37 percent. This is a 2.80 percent decrease over sales of $178.600 million the same period last year.

Earnings

Earnings Misses

OPKO Health Q3 2024 Adj. EPS $(0.09), Inline, Sales $173.600M Miss $181.525M Estimate

Development Based On ModeX's MSTAR Technology To Prepare For Emerging Viral Threats

Biotech

General

ModeX Therapeutics Secures $35M BARDA Supplement For COVID Multispecific Antibodies And $16M For Influenza Program; Total BARDA Awards Now At $110M With Potential To Reach $205M If All Options Are Exercised

Will Support Sales And Marketing Of OPKO Products On Additional E-Commerce Platforms And Social Media Channels; Agreement Includes Exclusive Rights For Japanese Market, One Of The World's Largest E-Commerce Markets With $151B Revenue In 2023

NXPL

NextPlat Secures Four-Year Extension Of OPKO Healthcare E-Commerce Program In China And Expands Program To Japan

HC Wainwright &amp; Co. analyst Yi Chen reiterates OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Buy and maintains $3 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on OPKO Health, Maintains $3 Price Target

ENTX

Entera Bio And OPKO Health Announce PK/PD Results For Oral Oxyntomodulin Peptide Tablet Candidate, Showing Significant Systemic Exposure And Favorable PK Profile In Obesity And Metabolic Disorder Studies; Oral OXM Demonstrates Prolonged Systemic Exposure Comparable To Semaglutide

During the last three months, 4 analysts shared their evaluations of OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for OPKO Health, revealing an average target of $2.81, a high estimate of $3.00, and a low estimate of $2.25. Highlighting a 9.94% decrease, the current average has fallen from the previous average price target of $3.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1726585238_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive OPKO Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$2.25</td>
<td>$1.50</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OPKO Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of OPKO Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for OPKO Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of OPKO Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OPK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OPKO Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into OPKO Health's Background</h2>
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
<h3>Key Indicators: OPKO Health's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: OPKO Health's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -31.36%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: OPKO Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -5.66%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): OPKO Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.78%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): OPKO Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.52%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: OPKO Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For OPKO Health

Piper Sandler analyst Edward Tenthoff reiterates OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Overweight and maintains $3 price target.

Piper Sandler Reiterates Overweight on OPKO Health, Maintains $3 Price Target

The acquisition includes&nbsp;BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey, including certain patient service centers (PSCs), customer contracts and operating assets, which currently generate approximately $100 million in annual revenue.

Laboratory Corporation Of America Holdings

Labcorp Has Completed The Acquisition Of Select Assets Of And Opko Health's Bioreference Health For $237.5M

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and raises the price target from $1.5 to $2.25.

Barrington Research Maintains Outperform on OPKO Health, Raises Price Target to $2.25

OPKO Health shares are trading higher after the company reported better-than-expected Q2 EPS results.

OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.09) by 88.89 percent. The company reported quarterly sales of $182.200 million which missed the analyst consensus estimate of $185.190 million by 1.61 percent. This is a 31.35 percent decrease over sales of $265.400 million the same period last year.

Earnings Beats

OPKO Health Q2 2024 GAAP EPS $(0.01) Beats $(0.09) Estimate, Sales $182.200M Miss $185.190M Estimate

Opko Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) shares are trading higher Thursday after the company announced a $100 million <a href="https://www.benzinga.com/pressreleases/24/07/g39835824/opko-health-announces-100-million-share-repurchase-program">share repurchase program.</a>
The Details:
Opko said it expects to fund the repurchase program from existing cash and cash equivalents, and future cash flows. The company had approximately 697 million shares outstanding as of June 30, 2024, and the new authorization represents approximately 10.1% of shares outstanding at the current stock price.
Read Next:<a href="https://www.benzinga.com/news/earnings/24/07/39826835/discover-reports-better-than-expected-q2-results-heres-the-details"> Discover Reports Better-Than-Expected Q2 Results: Here&#8217;s The Details</a>
&#8220;We believe OPKO&#8217;s shares are significantly undervalued and offer an attractive investment opportunity. Buying back shares supports our conviction in OPKO&#8217;s strategy as we continue to advance our pipeline in the clinic and streamline our diagnostic segment on a path to profitability,&#8221; said Phillip Frost, M.D., CEO of Opko Health.&nbsp;
Additionally, Opko announced a $250 million non-dilutive note <a href="https://www.benzinga.com/news/24/07/39827620/why-opko-health-shares-are-up-after-hours">purchase agreement </a>with HealthCare Royalty (HCRx) after the market close Wednesday. Opko said the purchase agreement is secured by its profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA, a once-weekly treatment to treat pediatric growth hormone deficiency.
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Opko Health shares are moving on heavy volume and are trading above the stock&#8217;s 50-day moving average of $1.31.&nbsp;
<h2 class="wp-block-heading">Should I Sell My OPK Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Opko Health have decreased by 27.39% in the past year. An investor who bought shares of Opko Health at the beginning of the year would take a loss of $0.03 per share if they sold it today. The stock has risen 24.15% over the past month, meaning an investor who bought shares on June 1 would see a capital gain of $0.12.
Opko Health shares have an all-time high of $5.15, representing 234.55% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Opko Health stock currently has an RSI of 84.21, indicating overbought conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
OPK Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Opko Health shares are up 3.87% at $1.47 at the time of publication Thursday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39827454/what-happened-with-intel-stock-today">What Happened With Intel Stock Today?</a></li>
</ul>
Image: Shutterstock

Opko Health Stock Is Climbing: What's Going On?

U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday.
Shares of Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) rose during Thursday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39839582/cintas-beats-expectations-with-strong-q4-earnings-sets-ambitious-fy25-revenue-target">quarterly EPS and revenues</a>.
Cintas reported fourth-quarter earnings per share of $3.99, beating the street view of $3.80. The company registered quarterly revenues of $2.471 billion, beating the street view of $2.468 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Cintas shares gained 5.3% to $758.25 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) shares gained 47.6% to $37.29 after the company and Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) jointly announced that Darden will acquire Chuy's Holdings.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) jumped 19% to $2.0407. Amphenol announced plans to acquire mobile networks businesses from CommScope.</li>
<li>ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) shares rose 14.7% to $21.74.</li>
<li>Virtu Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) surged 13.2% to $26.61 after the company reported better-than-expected second-quarter financial results.</li>
<li>D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) shares gained 10.6% to $174.29 after the company reported better-than-expected third-quarter financial results and revised its FY24 guidance. Also, the company authorized a new $4 billion share repurchase.</li>
<li>OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) rose 8.5% to $1.54. The company announced a $100 million share repurchase program.</li>
<li>Canadian Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) surged 8.3% to $17.89.</li>
<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) rose 7.5% to $59.12. HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterated Legend Biotech with a Buy and maintained a $73 price target.</li>
<li>Infosys Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) gained 7.4% to $22.07 as the company reported first-quarter revenue growth of 2.5% in constant currency terms year-on-year to $4.71 billion, beating the analyst consensus estimate of $4.65 billion.</li>
<li>Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) rose 7.4% to $85.29. Root is scheduled to host a conference call to discuss financial results for the second quarter on Wednesday, Aug. 7.</li>
<li>Materialise NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) jumped 7.2% to $5.85. Materialise is expected to release financial results for the second quarter on Wednesday, July 31.</li>
<li>BankUnited, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) gained 6.6% to $36.95 after the company reported better-than-expected quarterly financial results.</li>
<li>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) gained 6.5% to $260.95 after the company completed the acquisition of Cupertino Electric.</li>
<li>Meritage Homes Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) rose 6.1% to $201.54.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) rose 6% to $135.83 in sympathy with D.R. Horton, which reported better-than-expected third-quarter financial results.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) gained 5.2% to $8.76 after the Financial Times reported that the company has discussed plans to split its digital streaming and studio businesses from its legacy television networks.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) gained 4.4% to $35.97.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39837094/jim-cramer-can-bless-general-dynamics-its-great-not-expensive">Jim Cramer &#8216;Can Bless&#8217; General Dynamics: &#8216;It&#8217;s Great, Not Expensive</a>&#8216;</li>
</ul>

Intraday Update

Markets

Trading Ideas

CHUY

COMM

CSIQ

CTAS

INFY

INTC

LEGN

MTLS

ROOT

VIRT

ZIMV

Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday

Opko Health shares are trading higher. The company announced a $100 million share repurchase program.

OPKO Health Q3 Earnings Preview

Here are the major earnings after the close today

OPKO Health GAAP EPS of $0.03 beats by $0.12, revenue of $173.6M misses by $7.93M

Reports Q3 revenue $173.6M, consensus $181.52M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...

Opko Health reports Q3 EPS 3c, consensus (9c)

OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript

Opko Health ( ($OPK) ) has released its Q3 earnings. Here is a breakdown of the information Opko Health presented to its investors. OPKO Health, In...

OPKO Health Shows Strategic Progress in Q3 2024

Barrington analyst Michael Petusky has maintained their bullish stance on OPK stock, giving a Buy rating today. Michael Petusky has given his Buy r...

OPKO Health: Strategic Maneuvers and Future Profitability Drive Buy Rating

Latest data shows the largest indicative borrow rate increases among liquid option names include: Eldorado Gold (EGO) 4.16% +3.52, GlycoMimetics (G...

Largest borrow rate increases among liquid names

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Myomo (MYO – Research Report), Ionis Pharmaceuticals...

Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Ionis Pharmaceuticals (IONS) and Opko Health (OPK)

Latest data shows the largest indicative borrow rate increases among liquid option names include: Tenaya Therapeutics (TNYA) 119.73% +9.84, Satello...

AAOI

AAON

ACHR

ACHV

ADMA

ADPT

AEYE

AFRM

AISP

AKAM

ALLO

ALRM

ALTM

AMPL

AMRC

ANET

ARCT

ARLO

ARRY

ASLE

CHPT

DOCS

DVAX

FIVN

FNKO

FOSL

GLYC

GRRR

GSBD

GTBIF

HASI

HEAR

INDI

INGN

IONS

NWSA

OPEN

OUST

PACB

PARA

PBPB

PBYI

PHUN

PINS

PODD

PRCH

PSNY

PSNYW

PTCT

PTMN

QDEL

RCEL

RCMT

RDFN

REZI

RIGL

RILY

RIVN

SAND

SATL

SEMR

SENS

SERV

SIGA

TNYA

UVXY

XPEV

Press Releases

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024

Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®

OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference

NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer

OPKO Health's ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck

BABA

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

Castle Biosciences

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Guardant Health

Hims & Hers Health, Inc. Class A Common Stock

Hims & Hers Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Holdings

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

Option Care Health

Premier

Pennant Gr

Privia Health Gr

RadNet

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Hldgs

HC Wainwright & Co.

Barrington Research

Piper Sandler

옵코 헬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>)의 주가는 수요일 시장 마감 후 시간외 거래에서 상승했다. 이 회사는 헬스케어 로열티(HCRx)와 2억 5천만 달러 규모의 희석되지 않은 채권 구매 <a href="https://www.benzinga.com/pressreleases/24/07/g39825467/opko-health-and-healthcare-royalty-enter-into-250-million-note-purchase-agreement-secured-by-ngenl">계약을 체결</a>했다고 발표했다.
세부 내용: 옵코는 소아 성장 호르몬 결핍증을 치료하기 위한 주 1회 치료제인 엔젤라(NGENLA)와 관련된 라이선스 계약에 따라 화이자로부터 받은 이익 지분 지급으로 구매 계약이 보장된다고 말했다.
이 채권 구매 계약에 따라 발행된 2억 5천만 달러 규모의 채권에는 연 4%에 연 7.5%를 더한 3개월 SOFR(Secured Overnight Financing Rate) 이자가 붙는다. 해당 채권의 최종 만기일은 2044년 7월이며 처음 4년 동안은 이자만 지불하면 된다.
"HCRx와의 이번 거래를 통해 옵코는 단기적으로 NGENLA의 이익 지분 지불의 상당 부분을 보유하고 장기적으로 상승 여력을 제공할 수 있다. 또한 이를 통해 옵코는 화이자로부터 남은 잠재적 마일스톤 지불액인 1억 달러의 모든 혜택을 유지할 수 있다"고 옵코의 CEO인 필립 프로스트 박사(Phillip Frost, M.D.)가 말했다.
&#8220;게다가 다중특이적 항체 프로그램을 포함한 연구 개발 활동을 발전시키고 잠재적으로 보통주 및 전환사채의 주식을 환매할 수 있는 비희석 자본 및 재정적 유연성을 제공한다.&#8221;
OPK 주가 움직임: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noopener">Benzinga Pro</a>에 따르면, 옵코 헬스 주식은 수요일 시간외 거래에서 7.73% 상승한 1.53달러에 거래되었다.
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

OPKO Health

뉴스

에 대한 최신 뉴스 OPKO Health (NASDAQ:OPK) 주식

목요일, 7월 18, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌